P21 (BDNF-mimetic peptide)

CognitiveNeurotrophic fragment / researchExperimental

Short nootropic peptide associated with Cerebrolysin-derived fragments in research catalogs. Distinct from the p21 CDK inhibitor protein. Not FDA-approved.

Calculate Dose

For research use only.

Key Facts

CAS: —
Molecular Weight (MW): ≈2292 g/mol
Half-life: Unknown (preclinical)
Unit: mcg
Administration Route: —
Frequency: —
Last updated: 8/23/2026
Targets: Neurotrophic signaling (claimed)

Overview

Short nootropic peptide associated with Cerebrolysin-derived fragments in research catalogs. Distinct from the p21 CDK inhibitor protein. Not FDA-approved.

Protocol

Dosage Range: Preclinical research only
Frequency: —
Cycle: —
Administration Route: —
Reconstitution Guide: —

Science

Mechanism of Action

Marketed as a BDNF-pathway peptide; published identity is inconsistent across vendors. Related ADNP/NAP literature should not be assumed to apply to every P21 vial.